Numerous collaborative initiatives with the final aim of drug repurposing were objects of debate, among wich: The AZ Open Innovation program, the NIH National Center for Advancing Translational Sciences (NCATS) program: Discovering New Therapeutic Uses for Existing Molecules, the Medical Research Council (MRC) and AstraZeneca (AZ) Mechanisms of Human Disease Initiative, The Clinical and Translational Science Award (CTSA) Pharmaceutical Assets Portal, European College of Neuropsychopharmacology (ECNP) Medicines Chest Program, Pfizers SpringWorks Program, the AstraZeneca/National Research Program for Biopharmaceuticals (NRPB) partnership in Taiwan, the Roche/Broad Institute Collaboration, and the Drugs for Neglected Diseases Initiative (DNDI), the Clinical Development Partnerships Initiative (Krishnamurthy et al., 2022)
That is exactly the point the number most readers arrive with is the one number on this page that cannot be cited to anything
D'arino A, Caputo S, Bellei B
Lets get to it
We believe in a patient-centric approach, focusing on open communication, safety, and comfort
Laboratory research commonly explores Melanotan 1 peptide in studies involving peptide chemistry, receptor biology, molecular signalling, and biochemical analysis under controlled experimental conditions